ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה וממס להכנת תמיסה להזרקה - moroctocog alfa 2000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 1000 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 2000 iu - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה מיובשת בהקפאה להזרקה - moroctocog alfa 250 iu/vial - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

ישראל - עברית - Ministry of Health

neopharm ltd - piperacillin as sodium 2 g/vial; tazobactam sodium 0.25 g/vial - powder for solution for injection - piperacillin and enzyme inhibitor - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. tazocin in combination with an aminoglycoside, is indicated for suspected bacterial infections in neutropenic adults or children above 2 years. appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

ישראל - עברית - Ministry of Health

neopharm ltd - piperacillin as sodium 4 g; tazobactam sodium 0.5 g - powder for solution for injection - piperacillin and enzyme inhibitor - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. tazocin in combination with an aminoglycoside, is indicated for suspected bacterial infections in neutropenic adults or children above 2 years. appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

ישראל - עברית - Ministry of Health

neopharm ltd - piperacillin as sodium 4 g; tazobactam as sodium 0.5 g - powder for solution for injection - piperacillin and enzyme inhibitor - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. tazocin in combination with an aminoglycoside, is indicated for suspected bacterial infections in neutropenic adults or children above 2 years. appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.